Used in the synthesis of SGLT2 inhibitors for diabetes treatment. Acts as an intermediate in pharmaceutical manufacturing, particularly in creating antidiabetic drugs that enhance glucose excretion through urine by blocking glucose reabsorption in the kidneys. Its structure supports selective binding to SGLT2 proteins, improving glycemic control. Employed in research and development for oral hypoglycemic agents due to its functional groups that allow further chemical modifications.